Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2024-11-13 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
辰欣药业股份有限公司2024年半年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from a company regarding the implementation of a dividend distribution for the 2024 half-year period. It details the dividend per share, relevant dates for record and payment, tax treatment, and the shareholder meeting approval. The document length is about 2600 characters, which is relatively short and focused solely on dividend distribution details. It does not contain comprehensive financial statements or analysis, nor is it a full report. It is clearly an announcement of dividend amount and payment details, matching the definition of 'Notice of Dividend Amount (DIV)'.
2024-11-13 Chinese
辰欣药业股份有限公司关于2024年第三季度业绩说明会召开情况的公告
Call Transcript Classification · 95% confidence The document is titled as an announcement regarding the holding of the 2024 third quarter earnings explanation meeting (业绩说明会). It details the date, participants, and the Q&A session with investors about the company's third quarter performance. The text includes questions and answers about business segments, sales, and future outlook, typical of an earnings call or earnings explanation meeting. The document length is about 1993 characters, which is relatively short and mainly describes the event and Q&A rather than providing full financial statements or detailed financial analysis. This matches the characteristics of a Call Transcript (CT) or an Earnings Release (ER). However, since it is a transcript of an earnings explanation meeting with Q&A, it fits best as a Call Transcript (CT).
2024-11-11 Chinese
辰欣药业股份有限公司关于股权激励限制性股票回购注销实施公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the repurchase and cancellation of restricted stock under an equity incentive plan due to an employee leaving the company. It details the number of shares repurchased and cancelled, the reasons, the board approvals, and legal opinions. It is not a financial report, earnings release, or management discussion. It is a specific corporate action announcement related to share repurchase and cancellation of restricted stock. This fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or share cancellations.
2024-10-30 Chinese
山东国曜琴岛（济南）律师事务所关于辰欣药业股份有限公司2020年限制性股票激励计划回购注销部分限制性股票相关事项的法律意见书
Regulatory Filings
2024-10-30 Chinese
辰欣药业股份有限公司关于召开2024年第三季度业绩说明会的公告
Call Transcript Classification · 70% confidence The document is an announcement about the scheduling and details of a 2024 third quarter earnings conference call (业绩说明会), including date, time, location, participants, and how investors can participate and ask questions. It references that the company's 2024 third quarter report has already been published on October 29, 2024, and this meeting is to explain and discuss that report. The document does not contain actual financial data or detailed financial statements but is an invitation and information about the upcoming earnings call event. According to the classification rules, such announcements about earnings calls or investor meetings are classified as Call Transcript (CT) if they contain the transcript, or Investor Presentation (IP) if they are presentations. However, this document is a notice of the earnings call event itself, not the transcript or presentation. It is not a report publication announcement (RPA) because it is about a meeting, not the report release. The best fitting category is Call Transcript (CT) as it relates to the earnings explanation meeting, even though it is an announcement of the meeting rather than the transcript itself. Given the document length and content, confidence is moderate.
2024-10-30 Chinese
辰欣药业股份有限公司第五届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company regarding the approval of the company's 2024 third quarter report. It states that the Supervisory Board has reviewed and approved the Q3 report and confirms its compliance with relevant laws and regulations. However, the actual 2024 third quarter report is not included in this document; instead, it refers readers to the full report published on the Shanghai Stock Exchange website. The document length is short (881 characters) and serves as an official announcement of the Supervisory Board's resolution rather than the report itself. According to the 'Menu vs Meal' rule, this is an announcement related to an interim/quarterly report, not the report itself. Therefore, the correct classification is Regulatory Filings (RNS), as it is a regulatory announcement about the approval of the quarterly report, not the report containing substantive financial data itself.
2024-10-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.